NASDAQ:FDMT - 4D Molecular Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.50
  • Forecasted Upside: 83.91 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$24.74
▼ -0.61 (-2.41%)
1 month | 3 months | 12 months
Get New 4D Molecular Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FDMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FDMT

Average Price Target: $45.50
▲ +83.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for 4D Molecular Therapeutics in the last 3 months. The average price target is $45.50, with a high forecast of $47.00 and a low forecast of $44.00. The average price target represents a 83.91% upside from the last price of $24.74.

Buy

The current consensus among 3 polled investment analysts is to buy stock in 4D Molecular Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2021Evercore ISIInitiated CoverageOutperformN/A
1/5/2021Bank of AmericaInitiated CoverageBuy$47.00N/A
1/5/2021The Goldman Sachs GroupInitiated CoverageNeutral$44.00N/A
(Data available from 6/21/2016 forward)

4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $24.74
Low: $23.83
High: $25.09

50 Day Range

MA: $30.43
Low: $24.74
High: $38.70

52 Week Range

Now: $24.74
Low: $23.83
High: $55.11

Volume

202,300 shs

Average Volume

144,172 shs

Market Capitalization

$661.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 4D Molecular Therapeutics?

The following Wall Street research analysts have issued research reports on 4D Molecular Therapeutics in the last twelve months: Bank of America Co., Evercore ISI, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for FDMT.

What is the current price target for 4D Molecular Therapeutics?

2 Wall Street analysts have set twelve-month price targets for 4D Molecular Therapeutics in the last year. Their average twelve-month price target is $45.50, suggesting a possible upside of 83.9%. Bank of America Co. has the highest price target set, predicting FDMT will reach $47.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $44.00 for 4D Molecular Therapeutics in the next year.
View the latest price targets for FDMT.

What is the current consensus analyst rating for 4D Molecular Therapeutics?

4D Molecular Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FDMT will outperform the market and that investors should add to their positions of 4D Molecular Therapeutics.
View the latest ratings for FDMT.

What other companies compete with 4D Molecular Therapeutics?

How do I contact 4D Molecular Therapeutics' investor relations team?

The company's listed phone number is 510-505-2680. The official website for 4D Molecular Therapeutics is www.4dmoleculartherapeutics.com.